Avinger Inc. (NASDAQ:AVGR)’s share price was down 2.5% on Thursday . The stock traded as low as $4.26 and last traded at $4.29, with a volume of 128,122 shares traded. The stock had previously closed at $4.40.

Several equities analysts have recently weighed in on AVGR shares. Canaccord Genuity reissued a “buy” rating on shares of Avinger in a research note on Tuesday, July 12th. Zacks Investment Research downgraded shares of Avinger from a “hold” rating to a “sell” rating in a research note on Monday, May 9th. Finally, BTIG Research reaffirmed a “buy” rating and set a $18.00 target price on shares of Avinger in a research note on Friday, July 15th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $15.75.

The company has a 50-day moving average price of $5.50 and a 200 day moving average price of $10.27. The stock’s market cap is $52.65 million.

Avinger (NASDAQ:AVGR) last posted its quarterly earnings results on Monday, August 1st. The medical device company reported ($1.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.15) by $0.09. The company had revenue of $4.70 million for the quarter, compared to analyst estimates of $3.05 million. On average, analysts predict that Avinger Inc. will post ($4.16) EPS for the current fiscal year.

In related news, CEO Jeffrey M. Soinski purchased 57,100 shares of the stock in a transaction dated Tuesday, August 16th. The shares were acquired at an average cost of $3.50 per share, with a total value of $199,850.00. Following the purchase, the chief executive officer now directly owns 59,345 shares in the company, valued at approximately $207,707.50. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.